Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

GLP-1 is a biological pathway—not the name of one product

Glucagon-like peptide-1 (GLP-1) is an incretin hormone involved in glucose-dependent insulin signalling, glucagon regulation, gastric emptying and appetite-related pathways. A GLP-1 receptor agonist is a molecule designed to activate that receptor; the phrase does not make every molecule, formulation or product interchangeable.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide is an investigational molecule designed to activate GIP, GLP-1 and glucagon receptors. Those receptor profiles, as well as formulation, exposure and trial population, must remain attached to any comparison.

Evidence should become more specific as a claim becomes more consequential.

The endpoint determines what a GLP-1 trial can answer

GLP-1-related trials may measure glycated haemoglobin, body-weight change, treatment discontinuation, cardiovascular events or other outcomes. These are different research questions. A change in a metabolic marker is not interchangeable with a demonstrated clinical outcome, and a weight-focused trial does not automatically answer a cardiovascular question.

The SELECT trial, for example, enrolled adults with established cardiovascular disease and overweight or obesity but without diabetes, and used a prespecified composite cardiovascular endpoint. Retatrutide phase 2 studies used different populations, comparators and primary endpoints. The headline should never be separated from those design choices.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

Regulatory status and material identity are separate evidence layers

FDA states that unapproved GLP-1 products do not undergo its review for safety, effectiveness and quality before marketing, and it distinguishes approved active ingredients from other salt forms or unapproved versions. Clinical evidence for an authorized product cannot verify a separately sourced material.

Retatrutide remains investigational. A trial result does not establish the identity, purity, sterility, stability, safety or performance of a research-only sample. This article provides evidence interpretation only and contains no dosing, administration or treatment guidance.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 1 August 2026.

  1. U.S. FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated 2026.
  2. Lincoff et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. PMID 37952131.
  3. Jastreboff et al. Triple-hormone-receptor agonist retatrutide for obesity—phase 2 trial. N Engl J Med. 2023. PMID 37366315.
  4. Rosenstock et al. Retatrutide for people with type 2 diabetes—randomized phase 2 trial. Lancet. 2023. PMID 37385280.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.